The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research, population science and patient care. In keeping with our commitment to contemporary topics and scientific advance on a global scale, the Journal has established a section dedicated to the COVID-19 pandemic with an accelerated peer review, decision, and publication of scholarly review papers, observational studies and randomized clinical trials that will inform scientific undertakings and patient management.

The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular medicine. Published works will also define platforms for translational research, drug development, clinical trials, new drugs and devices, and patient-directed applications. The Journal of Thrombosis and Thrombolysis' integrated format will expand the reader's knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular medicine.

The Journal seeks original manuscripts devoted to fundamental science in cardiovascular disease, laboratory investigation, pharmacogenetics, clinical research, global health, population science, and epidemiology. State-of-the-art reviews, position papers and editorials will be summoned by invitation from the editor or an appointed guest editor. The Journal will publish special issues and supplements from national and international symposia and scientific committees in a timely fashion by working closely with organizers and contributing authors.

Manuscripts submitted must not be under consideration by another journal and should not have been published elsewhere in similar form. All articles will be reviewed by a minimum of two highly qualified referees. All clinical trials being considered for publication will also be reviewed by a statistician. A response will be provided within 2-3 weeks of receipt.
  94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again

Journal information

Editor-in-Chief
  • Richard Becker
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

2.054 (2019)
Impact factor
2.123 (2019)
Five year impact factor
25 days
Submission to first decision
70 days
Submission to acceptance
468,636 (2020)
Downloads

Latest issue

Volume 51

Issue 4, May 2021

Special Issue: New Perspectives in Cardio-Oncology: More than Anthracyclines and Cardiomyopathy

Latest articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$79.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
1573-742X
Print ISSN
0929-5305
Abstracted and indexed in
  1. BFI List
  2. CNKI
  3. Chemical Abstracts Service (CAS)
  4. Current Contents/Clinical Medicine
  5. Dimensions
  6. EBSCO Biomedical Reference Collection
  7. EBSCO Discovery Service
  8. EMBASE
  9. Google Scholar
  10. INIS Atomindex
  11. Institute of Scientific and Technical Information of China
  12. Japanese Science and Technology Agency (JST)
  13. Journal Citation Reports/Science Edition
  14. Medline
  15. Naver
  16. OCLC WorldCat Discovery Service
  17. Pathway Studio
  18. ProQuest Biological Science Database
  19. ProQuest Central
  20. ProQuest Health & Medical Collection
  21. ProQuest Health Research Premium Collection
  22. ProQuest Medical Database
  23. ProQuest Natural Science Collection
  24. ProQuest Neurosciences Abstracts
  25. ProQuest Pharma Collection
  26. ProQuest SciTech Premium Collection
  27. ProQuest-ExLibris Primo
  28. ProQuest-ExLibris Summon
  29. Reaxys
  30. SCImago
  31. SCOPUS
  32. Science Citation Index Expanded (SciSearch)
  33. Semantic Scholar
  34. TD Net Discovery Service
  35. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Science+Business Media, LLC, part of Springer Nature